We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genetix Grp | LSE:GTX | London | Ordinary Share | GB0001276863 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 84.00 | GBX |
Genetix Grp (GTX) Share Charts1 Year Genetix Grp Chart |
|
1 Month Genetix Grp Chart |
Intraday Genetix Grp Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/8/2009 | 11:12 | Genetix Ticking Away | 16 |
| 10/2/2007 | 21:59 | GENETIX GROUP!!!! watch????? | 29 |
| 12/8/2003 | 10:48 | Genetix - management to make bid approach | 11 |
| 21/4/2003 | 11:54 | GENETIX GROUP SOULD HAVE (PROMISING) INTERIMS | 13 |
| 02/2/2001 | 19:43 | GENETIX (GTX) Interesting day | 25 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/4/2009 15:15 by stegrego Bit worried here that although they are leaders at the moment, what happens if someone invents a new tech? Although i suppose the same could be said for many a share.Also, wouldnt want to buy in after such a spike caused purely by the tipsheet. Interesting share though. If it goes back into the 40s then i might look again. |
Posted at 16/4/2009 15:02 by masurenguy Price shot up by over 25% after being tipped by RHPS on April 3rd ! |
Posted at 15/1/2009 08:36 by darlocst Trading statement out today. Confirms GTX are in line with expectations."Charles de Rohan, Chief Executive of Genetix, commented: "We made further good progress in 2008 despite the wider economic conditions and volatile exchange rate markets. Our strategy of investing in the business to drive top line growth and underlying profitability and earnings per share is bearing fruit and positions us well to deliver sustained shareholder value. "The Group is profitable, financially strong and benefits from a number of defensive qualities. We continue to tightly manage our cost base in line with the current economic trading environment. With world class products and deep customer relationships, the business is well placed and able to meet the opportunities and challenges for the coming year" Market cap = £39.13m Cash = £15.2m EV = £24m In line with market expectations for FY 2008 confirmed, which are: EPS = 6p PBT = £4.76m They will gain further benefit from the weak GBPUSD exchange rate over the coming year & have the possibility of using that large cash pile to make earning enhancing acquisitions. Stripping out the cash puts GTX on a PE of less than 6 for FY2008, which for a company with a large cash pile, growing earnings in a traditionally defensive sector looks good value. I continue to hold. |
Posted at 03/11/2008 16:45 by darlocst I bought some GTX today.No debt, half market cap covered by cash, positive cash flow, sales growth of 20% per year. 44% of earnings in dollars last year so the exchange rate will provide a nice boost going forward. New CEO joined earlier this year bringing a greater sales focus. EPS forecast of 6p for 08, stripping out cash that puts them on a PE of just over 3. With the potential of using the cash pile for acquisitions to boost growth these look attractively priced. |
Posted at 19/4/2007 15:31 by darlocst Article from FT - April 4th. Long but well worth a read.---- Mark Reid has a homely way to describe what his company does: "Think of companies that make the kit to produce beer. We are doing a similar job to them." But the "beer" referred to by the chief executive of Genetix is a concoction of proteins and other genetic fragments that offer the potential to form new molecules useful to pharmaceutical companies. Genetix, based in New Milton, Hampshire, is one of a few companies in the world making the complicated machines that help in development and production of new pharmaceutical products based on biotechnology. Biotech companies use Genetix equipment to analyse samples and assess whether their properties make them suitable drugs. Genetix also makes small quantities of the substances for testing or as a prelude to full-scale production. For a manufacturing company with a strong technology bias, it may seem surprising that Genetix's 51- year-old founder is a former accountant, who taught himself chemistry in the 1980s after developing an urge to join the sector. Indeed, nearly all other businesses in this field were founded by scientists rather than accountants, but Mr Reid does not see this as a handicap: "I have taught myself what I need to know, and can leave all the really technical matters to other people," he says. His lack of scientific background appears to have done him no harm: his 59 per cent stake in Genetix is now worth £33m. After an initial foray into the basic industry of plastics moulding, Mr Reid founded Genetix in 1991. This is still a fledgling industry and steering a way through the many changes in the sector has required both dogged perseverence and an ability to change tack when required. The business of biotech instrumentation and the chemicals used with the machines enjoys total global sales of about $2bn (£1bn) a year. Genetix's competitors in this field are mainly from the US, and include big makers of scientific instruments such as Thermo Fisher, Bio-Rad Laboratories and PerkinElmer as well as more specialised biotech groups such as Applied Biosystems and Affymetrix. The development of such equipment was triggered by rapid advances in the past 20 or so years in gene-based techniques for fighting disease. "We are in the dawn of a new era of medicine in which a range of new treatments based on proteins and similar materials is becoming possible," says Mr Reid. But keeping abreast of industry trends not to mention coping with the vagaries of government funding, particularly in the US has not been easy. A number of Mr Reid's smaller competitors have either gone under or been swallowed up by bigger groups, making him a rare UK-based survivor in the sector. The US-based Genomic Solutions and the UK's Biorobotics, two small businesses making similar products to Genetix, have both in recent years passed into the hands of big companies, and are now both owned by Harvard Bioscience. In the late 1990s, government cash was pouring into the race to decode the human genome, prompting the industry to focus on the search for the structure of DNA. But now there is more emphasis on cell biology and practical ways to "harvest" proteins and similar materials that could be useful in therapy and diagnosis. So while Genetix started out by producing machines geared mainly to uncovering the structure of DNA samples, the company has since changed tack. Its latest families of machines which sell for up to £200,000 include equipment that analyses samples of cells, to check on their propensity to manufacture certain types of proteins that could become useful medicines, while also monitoring the rate at which they create such molecules. "We are getting some encouraging feedback from customers [in the pharmaceutical industry] that the machines are doing a useful job," says Mr Reid. Another positive sign for the company is that roughly half the expected sales in 2007 of about £27m are likely to come from products and specialist software introduced over the past year with particular contributions from the new "cell sample" machines plus software. Of special relevance to this last point is Genetix's £13.6m purchase last year of Applied Imaging, a California-based company specialising in the imaging software that is increasingly required in biotech-based instruments. Underlining the importance of the US to the biotech field, some 60 per cent of the company's revenues in 2007 is likely to come from North America, which is where it has 50 of its 165-strong staff, with most of the rest located in the New Milton headquarters just outside Bournemouth. Research and development is important to Genetix: some 40 per cent of its staff work in this field (including software) and only 20 in manufacturing all of whom work at the New Milton site. The company's share price reflects the shifts in the industry. After floating in 2000 at a share price of £1.50 this quickly rose to £2.50 only to slump to 25p in 2003 on the back of a fall in fortunes in the entire biotech sector, which was linked partly to a run of poor results from some leading biotech companies. After a better run of profits, however, Genetix's share price has rebounded to 80p. Last year, in recording pre-tax profits of £3.2m on sales of £15.5m, the company registered a pre-tax profit margin of 20 per cent. Having lasted the distance so far, Mr Reid names Renishaw as the company he would most like Genetix to emulate. This highly successful medium-sized UK-based business in measuring instruments, with annual sales of £173m, was set up in 1973 by Sir David McMurtry, who remains in charge as chairman and chief executive. "If I could create something like Renishaw, it would be fantastic," says Mr Reid. A timely injection of learning After starting out as an accountant with KPMG, Mark Reid decided there could be more to working life than spreadsheets and company audits. He decided to try manufacturing and in 1985 bought Plastic Injection, a Dorset-based moulding business that is now part of Jarden, a US company. "But I soon found out that making injection moulded plastic parts wasn't an easy business," Mr Reid says. "I had to do something different from all the competitors, or face severe problems." He achieved that partly thanks to a friend who was a chemistry lecturer at Southampton University. By sitting at the back of the friend's lecture room without enrolling on a course the ex-accountant absorbed some useful know-how about polymer chemistry. He learned enough to work out how to position Plastic Injection into an "upmarket" area of the plastics business in which it worked with novel and tough but mouldable plastics to form components used, for instance, in oil and gas pipelines. Another breakthrough came after some chance contacts in the late 1980s with scientists at the Imperial Cancer Research Fund in London, who asked Mr Reid to produce plastic components for a new family of genetic machines they wanted to develop as part of the effort to sequence the human genome. "We worked out how to make the parts and they (the scientists) were happy," Mr Reid says. "Then they asked us if we could make the whole machine .̴ He found a group of engineers who could do the technical work and started the biotechnology instrumentation company Genetix in 1991. Its first premises were the spare bedroom of David Norton, a former colleague who was a co-founder Genetix but left soon after to leave Mr Reid running it on its own. Genetix's first product, called the Qbot, worked out the significance of tiny samples of genetic fragments and was useful in analysing DNA samples. Based on the ICRF's designs, it sold for £60,000. |
Posted at 19/4/2007 15:30 by darlocst Anybody still holding these?New product release from Genetix, sounds pretty good. This is exactly the type of product, with value added from new acquisition AIS, that will mean GTX will grow their sales more than the forecast this year. AGM is on May 9th, hopefully an update on trading then. |
Posted at 22/1/2007 12:17 by sruk77 Good to see the price on the up with some decent volumes. The web site shows a press release for a new product and also a new newsletter, see; www.genetix.com This stick is ready to hit 85p before its next interim report. Recommended as a 'strong buy' and will continue to rise... =================== Wednesday, 17th January 2007 07:54 Genetix Group sees FY profits ahead of forecast, improved gross margins LONDON (AFX) - Cell biology company Genetix Group PLC said it expects its full year profits to be ahead of expectations due to improved gross margins and US dollar exchange gains, with sales excluding new acquisition Applied Imaging Corp in line with market expectations. The company said it expects Applied Imaging, which the company bought for 25.8 mln usd cash in November, to make a 'meaningful contribution' to the company's profitability over the period. newsdesk@afxnews.com =================== Wednesday, 22nd November 2006 09:06 Genetix completes acquisition of US-based Applied Imaging for 25.8 mln usd LONDON (AFX) - AIM-listed cell biology company Genetix Group PLC said it has completed the acquisition of US-based Applied Imaging Corp for about 25.8 mln usd cash. Genetix said the acquisition will increase its strength in cell imaging and analysis, allowing it to exploit 'growth opportunities' in both the drug discovery and clinical diagnostics markets. The company first announced an 18.3 mln usd cash bid for Applied Imaging on Sept 1 and since then had been forced to hike the offer several times by an unnamed rival bidder. =================== Wednesday, 22nd November 2006 08:18 UK smallcap opening - Genetix better as Applied Imaging deal completed LONDON (AFX) - Buyers came for Genetix Group, 7 pence better at 59-1/2, as the cell biology and health technology group completed the acquisition of Applied Imaging for around 25.8 mln usd cash (about 13.6 mln stg). |
Posted at 30/10/2006 19:35 by adam Is there a break fee if GTX decide too much? |
Posted at 20/3/2006 20:21 by tole Genetix "buy," target price raised LONDON, March 1 (newratings.com) - Analyst Jonathan Kwok of Panmure Gordon & (LSE: PMR.L - news) amp; Co maintains his "buy" rating on Genetix Group (LSE: GTX.L - news) (ticker: GTX (NASDAQ: GTXI - news) -GBX). The target price has been raised from 61p to 68p. In a research note published this morning, the analyst mentions that the company has reported its top-line and bottom-line for 2005 ahead of the estimates, primarily due to substantial gross margin expansion, mix shift to high-margin products and an increase in instrumentation sales. Genetix has posted a sequential decline in its R&D and sales & marketing costs and a sequential increase in its interest income for the year. Anyone any thoughts on this one - cash must pretty much underpin the price at this level. |
Posted at 03/3/2005 13:23 by games Just had a few days away, and its nice to come back to a little positive direction.I missed the results the other day Which after a quick glance look very reasonable, and wish them the best in gaining a decent slice of.... 'Our key priority in 2005 is to concentrate activity on the potentially significant markets within cell biology and penetrate these as quickly as possible' Also still a quite board, with a price that looks far from overstretched. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
